Short Communication - (2024) Volume 9, Issue 1
Received: 13-Dec-2023, Manuscript No. jmhmp-23-117519;
Editor assigned: 15-Dec-2023, Pre QC No. P-117519;
Reviewed: 27-Dec-2023, QC No. Q-117519;
Revised: 01-Jan-2024, Manuscript No. R-117519;
Published:
08-Jan-2024
, DOI: 10.37421/2684-494X.2024.9.115
Citation: Rase, Rong. “Novel Metallodrugs Based on Copper
and Having Anti-Invasive Properties.” J Mol Hist Med Phys 9 (2024): 115.
Copyright: © 2024 Rase R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Metallodrugs, which are coordination compounds containing metal ions, have gained significant attention in the field of medicinal chemistry due to their versatile properties and potential applications in the treatment of various diseases, including cancer. Copper-based metallodrugs have emerged as promising candidates for therapeutic intervention, particularly for their anti-invasive properties. In this article, we will explore the development and mechanisms of novel metallodrugs based on copper and their potential to inhibit invasion in cancer cells. Copper is an essential trace element in the human body, playing critical roles in various biological processes, such as redox reactions, oxygen transport, and enzyme catalysis. However, copper can also exhibit toxic effects when present in excess or when its homeostasis is disrupted. These attributes of copper make it an intriguing target for the development of metallodrugs with therapeutic potential. The use of copperbased compounds in medicine dates back to ancient times, with copper salts being employed for their antimicrobial and wound-healing properties. Over the years, advances in coordination chemistry and our understanding of metalprotein interactions have led to the design of copper-based metallodrugs that are more selective and effective in targeting specific cellular processes [1].
Cancer remains one of the most challenging diseases to treat, largely due to its invasive nature. Metastasis, the spread of cancer cells to distant organs, is a key factor contributing to cancer-related mortality. To combat metastasis, researchers have explored the use of copper-based metallodrugs as potential anti-invasive agents. These metallodrugs exhibit a multifaceted approach to inhibiting cancer cell invasion, making them a compelling area of study in cancer therapy. Matrix Metalloproteinases (MMPs) are a family of enzymes responsible for remodeling the extracellular matrix, a complex network of proteins that provides structural support to tissues. Overexpression of MMPs is often associated with cancer invasion and metastasis. Copperbased metallodrugs have shown promise in inhibiting MMP activity.
One such metallodrug is copper (II)-pyridine complexes, which have demonstrated the ability to modulate MMPs. These complexes interact with the active sites of MMPs and inhibit their enzymatic activity, preventing the degradation of the extracellular matrix. This, in turn, hinders cancer cell invasion and the formation of secondary tumors. Copper-based metallodrugs can also exploit the redox properties of copper to induce oxidative stress in cancer cells. By generating Reactive Oxygen Species (ROS) within the tumor microenvironment, these metallodrugs can disrupt the invasive behavior of cancer cells. One example is copper (II) complexes with ligands that release copper ions in response to specific cellular conditions. The released copper ions can trigger ROS production, leading to oxidative damage and impaired invasion. Angiogenesis, the formation of new blood vessels, is a critical process in tumor growth and metastasis. Copper-based metallodrugs have demonstrated anti-angiogenic effects by targeting factors involved in angiogenesis, such as Vascular Endothelial Growth Factor (VEGF). These metallodrugs can inhibit the expression and activity of VEGF, leading to reduced blood vessel formation and, consequently, impaired tumor invasion [2].
Copper-based metallodrugs can interfere with specific signaling pathways that promote cancer cell invasion. For instance, the Wnt/β-catenin pathway is implicated in the invasiveness of various cancers. Metallodrugs can target components of this pathway, inhibiting its activation and reducing cancer cell migration and invasion. Recent advances in metallodrug development have led to the creation of novel copper-based compounds with enhanced antiinvasive properties. These compounds are designed to be highly selective and effective against cancer cells while minimizing toxicity to healthy tissues. These complexes can specifically target cancer cells that overexpress certain receptors, making them more selective and less harmful to normal cells. The peptide ligands act as homing devices, guiding the copper complex to the tumor site. This selective targeting minimizes off-target effects and enhances the anti-invasive properties of the metallodrug [3].
Copper nanoparticles are a novel approach to copper-based metallodrugs. These nanoparticles can be designed with specific surface modifications that allow them to target cancer cells and deliver copper ions directly to the tumor site. The controlled release of copper ions within the tumor microenvironment can induce oxidative stress and inhibit cancer cell invasion. Copper-Organic Frameworks (COFs) represent a class of coordination compounds with intriguing properties for drug delivery and therapy. COFs can be engineered to encapsulate copper ions and release them in response to specific triggers, such as changes in pH or redox conditions within the tumor. This controlled release of copper ions can disrupt invasive processes while minimizing systemic toxicity [4].
To understand the effectiveness of novel copper-based metallodrugs in inhibiting cancer cell invasion, it is essential to delve into the underlying mechanisms. Copper-based metallodrugs target MMPs and prevent the degradation of the extracellular matrix. This leads to decreased cancer cell motility and invasion into surrounding tissues. The generation of ROS by copper-based metallodrugs disrupts the cellular redox balance, leading to oxidative stress. Cancer cells are more susceptible to oxidative damage, and this impairs their invasive potential. By inhibiting angiogenesis, copper-based metallodrugs reduce the blood supply to tumors, making it challenging for cancer cells to migrate and establish metastatic sites [5].
Copper-based metallodrugs interfere with signaling pathways that promote invasion. By blocking these pathways, the drugs reduce the migratory and invasive capacities of cancer cells. The promising results of preclinical studies have led to the exploration of copper-based metallodrugs in animal models and clinical trials. These investigations aim to assess the safety, efficacy, and anti-invasive properties of these compounds in a more physiologically relevant context. In vivo studies involving animal models have shown encouraging outcomes. Mouse models bearing human-derived xenograft tumors have demonstrated that copper-based metallodrugs can inhibit tumor growth and reduce metastasis. These studies provide valuable insights into the potential of copper-based metallodrugs in complex biological systems. Clinical trials involving cancer patients are essential to determine the safety and efficacy of novel metallodrugs. The trials typically assess parameters such as toxicity, dosage, and the impact of metallodrug treatment on cancer progression and metastasis.
None.
There is no conflict of interest by author.
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
